The Leukemia & Lymphoma Society® (LLS) is the largest voluntary health organization dedicated to funding research, finding cures and ensuring access to treatments for blood cancer patients.
Since 1949, LLS has been on the forefront of blood cancer advances, such as chemotherapies and stem cell transplantation, leading the way to the targeted therapies and immunotherapies that are saving thousands of lives today.
LLS is changing the landscape of cancer with more than 300 active research projects that explore different avenues of new and adventurous research; ones with promise and ones that will save lives not someday, but today.
Mission Moment Honoree Kelvin Yates, a multiple myeloma survivor pictured with his daughter Mariah Yates sharing their story at the 2018 Leukemia Ball.
Support LLS Year-Round
The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS exists to find cures and ensure access to treatments for blood cancer patients. We are the voice for all blood cancer patients and we work to ensure access to treatments for all blood cancer patients.
Leukemia survivor, Vishav and Steve Ubl, President & CEO of PhRMA at the 2016 Leukemia Ball. Vishav was diagnosed with leukemia at the age of 4. After more than three years of treatment, Vishav was declared cancer-free in 2012.
Leukemia survivor, Emily and her parents at the 2015 Leukemia Ball. Emily was the first pediatric patient to receive the ground-breaking CAR-T therapy, funded in part by LLS. In 2017, CAR-T therapy received FDA approval. Read more about this incredible breakthrough here
RESEARCH + IMPACT
As there are no means of preventing or early screening for most blood cancers, the LLS research agenda is focused on finding cures. LLS drives research in areas of unmet medical need, and helps to bridge the gap between academic discovery and drug development. LLS identifies and funds the most promising blood cancer research projects. In addition, it forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies.